The Art of Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Art of Investing

PICK 51.06

+2.3%

Dec 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Sun Tzu

10/30/2025 8:41:31 AM

Read Replies (1) of 10712

Phathom Q3 revenue up 25%, beats estimates
Oct 30, 2025, 07:19 GMT-4RefinitivLess than 1 min read

PHAT-0.07%
Overview

Phathom Q3 2025 revenue rises 25% quarter-over-quarter, beating analyst expectations
Company updates 2025 revenue guidance to $170–$175 mln, expects profitability in 2026
Cash operating expenses down 43% quarter-over-quarter, aligning with cost-saving plans

Outlook

Phathom updates 2025 revenue guidance to $170–$175 mln
Company expects operating profitability in 2026
Phathom anticipates VOQUEZNA exclusivity through May 2032

Result Drivers

VOQUEZNA PRESCRIPTIONS - 28% increase in filled VOQUEZNA prescriptions drove revenue growth, supported by strategic sales force retargeting efforts
COST SAVINGS - Significant reduction in operating expenses due to lower promotional spend and personnel costs
COMMERCIAL COVERAGE - Stable commercial coverage with over 80% of U.S. lives covered supports revenue growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$49.50 mln	$46.99 mln (8 Analysts)
Q3 Net Income		-$30 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $20.00, about 32.4% above its October 29 closing price of $13.53

Press Release:

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next